Natural Management
Evidence-based dietary, supplement, and gut health strategies for reducing psoriasis severity and flare frequency
Psoriasis is a chronic autoimmune skin condition in which the immune system triggers skin cells to multiply up to ten times faster than normal, producing the thick, red, silver-scaled plaques most people recognize. It affects around 2–3% of the global population and cycles through flares and remissions, with stress, infection, and dietary patterns among the most common triggers. While biologics and corticosteroids are the most potent pharmaceutical options, a growing evidence base supports omega-3 fatty acids, curcumin, gut health strategies, and anti-inflammatory eating as meaningful complements that can reduce flare frequency and severity [1][3].
Understanding the Inflammatory Drivers
Psoriasis is rooted in immune dysregulation — specifically, an overactivation of T-helper 17 (Th17) and Th1 cells that release inflammatory cytokines including IL-17, IL-23, and TNF-alpha. These signals accelerate keratinocyte (skin cell) proliferation far beyond the normal rate, producing the characteristic plaques. The inflammation is not confined to the skin: psoriasis carries elevated risk of cardiovascular disease, metabolic syndrome, psoriatic arthritis (affecting 20–30% of patients), and depression.
This systemic inflammatory backdrop means that interventions targeting inflammation broadly — omega-3 fats, antioxidants, gut microbiome modulation, stress reduction — have plausible pathways through which they can reduce disease activity, even if they don't directly address the root T-cell dysregulation.
Omega-3 Fatty Acids: Shifting the Inflammatory Balance
EPA and DHA from fish oil compete with arachidonic acid at the enzymatic level, producing leukotrienes and prostaglandins of the less-inflammatory 3-series rather than the 2-series molecules (PGE2, LTB4) that dominate psoriatic inflammation. An early landmark trial found significant reductions in itch, erythema, and scaling after 8 weeks of fish oil supplementation compared to placebo [1].
A 2020 systematic review of 18 randomized controlled trials found that fish oil monotherapy did not consistently reduce PASI (Psoriasis Area and Severity Index) scores on its own, but fish oil combined with conventional treatments — topical steroids, phototherapy, or systemic agents — produced significantly greater PASI reduction than conventional treatment alone [2]. This positions omega-3 supplementation as a complement to standard care rather than a replacement.
Practical guidance:
- 2–4g EPA+DHA daily for at least 12 weeks; dose appears to matter more than duration for skin-level effects
- Reducing omega-6 intake from seed oils (sunflower, soybean, corn) amplifies the benefit by lowering the arachidonic acid substrate pool
- Food sources: wild salmon, sardines, mackerel — regular fatty fish consumption may provide synergistic dietary pattern benefits beyond isolated supplementation
See our Omega-3 page and Seed Oils page for more context.
Curcumin: NF-kB Inhibition and Immune Modulation
Curcumin, the active compound in turmeric, is one of the most-studied natural compounds in psoriasis. Its primary mechanism is inhibition of NF-kB (nuclear factor kappa B), a master inflammatory transcription factor that drives cytokine production in psoriatic plaques. Curcumin also inhibits phosphorylase kinase — an enzyme specifically elevated in psoriatic skin — and reduces STAT3 signaling downstream of IL-6.
A 2008 prospective clinical trial using oral curcuminoid complex found that 79% of participants with moderate to severe psoriasis rated their response as good to excellent at 12 weeks, with meaningful PASI improvements [3]. A subsequent double-blind RCT found that patients receiving Meriva (a phospholipid-curcumin complex with enhanced bioavailability) alongside topical steroids had significantly greater PASI reductions and lower serum IL-22 levels — a key driver of keratinocyte hyperproliferation — than those on topical steroids alone [4].
Bioavailability is the critical variable: standard curcumin powder is poorly absorbed from the gut. Formulations with enhanced bioavailability (Meriva, BCM-95, Longvida, NovaSol) are consistently more effective in clinical trials.
Practical guidance:
- Meriva 500–1000mg twice daily or BCM-95 formulations have the strongest clinical evidence in psoriasis
- If using standard curcumin, combine with black pepper (piperine at 20mg) — piperine increases absorption up to 20-fold
- Allow at least 8–12 weeks to assess response; most RCTs ran 12 weeks
See our Turmeric/Curcumin page for formulation and dosing comparison.
The Gut-Skin Axis: Microbiome and Psoriasis
Psoriasis patients consistently show gut microbiome alterations: reduced microbial diversity, lower levels of Faecalibacterium prausnitzii (an important anti-inflammatory butyrate producer), depletion of Akkermansia muciniphila, and shifts in Firmicutes/Bacteroidetes ratios [5]. The gut and skin are immunologically linked: gut dysbiosis compromises intestinal barrier integrity, allowing bacterial fragments into systemic circulation, which triggers innate immune activation that amplifies the Th17 response driving psoriatic plaques.
Probiotic interventional studies in psoriasis show consistent but modest benefits. A 2020 review of clinical trials found that multi-strain probiotic supplementation reduced PASI scores significantly compared to placebo, with 66.7% of probiotic patients versus 41.9% of placebo patients achieving PASI-75 reduction in one controlled trial, alongside reductions in inflammatory cytokines [5].
Practical guidance:
- Multi-strain probiotics containing Lactobacillus rhamnosus, L. acidophilus, and Bifidobacterium longum are the most studied in psoriasis
- 8–12 weeks minimum for meaningful benefit; gut microbiome changes take time
- Fermented foods — kefir, kimchi, sauerkraut — support microbial diversity alongside targeted supplementation
- Prebiotic fiber from vegetables, legumes, and resistant starch feeds anti-inflammatory commensals including F. prausnitzii
See our Probiotics page, Leaky Gut page, and Gut-Brain Axis page for supporting strategies.
Vitamin D: Correcting a Common Deficiency
Psoriasis patients consistently show lower serum vitamin D levels than healthy controls, and there is a clear mechanistic reason: vitamin D receptor signaling in T cells normally suppresses the Th17 and Th1 responses that drive psoriasis. Topical vitamin D analogues (calcipotriol) are established first-line pharmaceutical treatments for plaque psoriasis, working locally to slow keratinocyte proliferation and reduce inflammation.
Oral vitamin D supplementation has a more mixed evidence base. A 2020 meta-analysis of RCTs found that supplementation improved psoriasis severity in vitamin D-deficient individuals but showed weaker effects in vitamin D-sufficient populations [6]. The implication is that correcting deficiency — rather than maximizing levels — is the appropriate goal.
Practical guidance:
- Test 25-OH vitamin D; levels below 30 ng/mL are common in psoriasis patients and indicate correctable deficiency
- 2,000–4,000 IU vitamin D3 daily, with vitamin K2 (100–200mcg MK-7) to support calcium routing
- Most benefit is adjunctive — correcting deficiency supports immune regulation but does not replace dietary and gut-focused strategies
See our Vitamin D page for general guidance on testing and dosing.
Dietary Patterns and Key Trigger Avoidance
Beyond specific supplements, several dietary patterns are associated with lower psoriasis severity:
- Mediterranean diet: Multiple retrospective and prospective studies show that Mediterranean diet adherence correlates with lower PASI scores and reduced flare frequency, likely through cumulative anti-inflammatory effects of olive oil polyphenols, omega-3 from fish, and diverse plant antioxidants
- Gluten-free diet: Psoriasis patients have a higher prevalence of celiac disease and elevated anti-gliadin antibodies; in the serologically positive subgroup, a gluten-free diet has been shown to measurably reduce PASI scores
- Alcohol: Worsens psoriasis significantly through multiple pathways — immune dysregulation, increased gut permeability, and direct skin effects — and reduces responsiveness to therapies
- Ultra-processed foods: High sugar, refined carbohydrates, and seed oils elevate systemic inflammatory markers; avoidance is a foundational dietary modification
Stress Management and the Psychoneuroimmune Connection
Psychological stress reliably triggers psoriasis flares through cortisol-mediated immune dysregulation and neuropeptide release — substance P and nerve growth factor activate mast cells and keratinocytes directly. Mind-body interventions including mindfulness meditation, yoga, and cognitive behavioral therapy have demonstrated measurable PASI reductions in several trials, particularly in patients who identify stress as a consistent flare trigger.
See our Meditation and Breathwork page and Yoga page for evidence on stress-modulating practices.
Evidence Review
Fish Oil RCT: Reduction in Itch, Erythema, and Scaling (Bittiner et al., 1988)
Bittiner et al. (PMID 2893189) conducted one of the first rigorous controlled trials of omega-3 supplementation in psoriasis. In this double-blind, randomized, placebo-controlled trial, 28 patients with chronic stable plaque psoriasis received either 10 capsules of MaxEPA fish oil daily (providing approximately 3.6g EPA and 2.4g DHA) or 10 olive oil placebo capsules for 8 weeks. At week 8, the fish oil group showed statistically significant reductions in itch (p<0.05), erythema (p<0.05), and scaling (p<0.05), with a trend toward reduced total body surface area affected.
The mechanistic interpretation centers on competitive inhibition: EPA displaces arachidonic acid as substrate for cyclooxygenase and 5-lipoxygenase enzymes, shifting prostaglandin synthesis toward the 3-series (PGE3, less potent) and leukotriene synthesis toward the 5-series (LTB5, far weaker than LTB4). LTB4, a potent neutrophil chemoattractant elevated in psoriatic plaques, is specifically suppressed. This provides a clear inflammatory pathway through which dietary omega-3 enrichment can reduce psoriatic activity at the skin level.
Strength of evidence: Moderate. The trial established the mechanistic proof-of-concept with a clean design but small sample (n=28). Subsequent large meta-analyses confirm a real but dose-dependent effect, most consistent when fish oil is combined with standard care rather than used alone.
Fish Oil Systematic Review: 18 RCTs (2020)
The 2020 systematic review (PMID 31995220) examined 18 randomized controlled trials evaluating fish oil and omega-3 components across diverse psoriasis populations and treatment contexts. The primary finding was that fish oil monotherapy did not significantly reduce PASI scores in pooled analysis, but fish oil combined with conventional treatments produced a significantly greater PASI reduction than conventional treatment alone. Fish oil supplementation also showed consistent benefit for pruritus (itch) reduction as a secondary outcome, even in trials showing no overall PASI effect.
This meta-analytic finding reconciles the conflicting individual trial results: earlier positive trials tended to use higher omega-3 doses (3–4g EPA+DHA/day) and combined fish oil with other interventions, while later negative trials frequently used lower doses in isolation. The combination benefit suggests omega-3s amplify rather than replace conventional treatment — a clinically useful framing.
Strength of evidence: Moderate. The 18-trial evidence base is the largest available for omega-3s in psoriasis and provides sufficient power to resolve the monotherapy vs. combination question.
Oral Curcumin in Moderate to Severe Psoriasis (Kurd et al., 2008)
Kurd et al. (PMID 18249471) conducted a prospective open-label clinical trial of oral curcuminoid C3 Complex in patients with moderate to severe psoriasis vulgaris (PASI >10). At 12 weeks, 79% of evaluable patients rated their response as "good" or "excellent" on global assessment; PASI scores decreased significantly from baseline. Curcumin was well tolerated with minimal adverse effects. This was among the first clinical demonstrations that systemic curcumin could produce clinically meaningful psoriasis improvements.
The mechanistic basis is strong: curcumin inhibits NF-kB in keratinocytes, T cells, and dendritic cells — reducing transcription of IL-17, IL-23, TNF-alpha, and IL-6. It also directly inhibits phosphorylase kinase, an enzyme elevated specifically in psoriatic but not normal skin, and suppresses JAK-STAT3 signaling activated by IL-6 and IL-22.
Strength of evidence: Moderate. The open-label design limits conclusions about placebo effect. Subsequent blinded trials using enhanced-bioavailability formulations (Meriva, BCM-95) have provided more rigorous confirmation. A 2022 meta-analysis (PMID 36120325) pooling 7 curcumin RCTs found consistent PASI improvement in combination therapy arms.
Curcumin (Meriva) as Adjuvant Treatment: Double-Blind RCT (Antiga et al., 2015)
Antiga et al. (PMID 26090395) conducted a randomized, double-blind, placebo-controlled trial in 63 patients with mild-to-moderate psoriasis vulgaris (PASI <10). Participants received either Meriva (2g/day, providing approximately 400mg curcumin as phospholipid complex) plus topical steroids, or topical steroids plus placebo for 12 weeks. The Meriva group achieved statistically significant greater reductions in PASI scores compared to placebo (p<0.001). Critically, serum IL-22 — a cytokine directly responsible for driving keratinocyte hyperproliferation in psoriasis — was significantly reduced in the Meriva group but not in the placebo group. Quality of life (DLQI) improved significantly more in the curcumin arm.
This trial is the most rigorous curcumin study in psoriasis to date. Meriva's phospholipid-complexed delivery system provides approximately 29-fold greater bioavailability than standard curcumin, which likely explains why the controlled evidence favors enhanced formulations. The IL-22 biomarker data mechanistically links the clinical improvement to the specific inflammatory pathway curcumin is expected to target.
Strength of evidence: High for Meriva specifically in mild-to-moderate psoriasis as adjuvant therapy. The blinded RCT design, biomarker confirmation, and clinically meaningful effect size make this the reference trial for curcumin in psoriasis.
Gut Microbiome and Therapeutic Effects of Probiotics (Chen et al., 2020)
Chen et al. (PMID 31803643) comprehensively reviewed the mechanistic evidence for gut-skin axis involvement in psoriasis and therapeutic implications of microbiome-targeted interventions. The gut dysbiosis signature in psoriasis is consistent across independent study populations: Faecalibacterium prausnitzii is depleted (correlating with disease severity), Akkermansia muciniphila is reduced (impairing mucosal barrier function), Candida and Ruminococcus species are elevated, and short-chain fatty acid (SCFA) production is globally diminished.
The causal mechanism involves multiple interconnected pathways: reduced butyrate from F. prausnitzii impairs regulatory T cell (Treg) induction and allows Th17 polarization; leaky gut allows lipopolysaccharide (LPS) entry into systemic circulation, activating TLR4-NF-kB signaling in skin immune cells; and microbiome-derived metabolites reach the skin via circulation to directly alter resident immune cell phenotypes. In controlled probiotic trials reviewed, supplementation reduced PASI scores significantly versus placebo, with 66.7% of probiotic patients achieving PASI-75 (versus 41.9% placebo), and serum IL-6 and TNF-alpha levels were reduced in probiotic arms.
Strength of evidence: Moderate. The mechanistic framework is well-supported by consistent observational data across populations. Interventional probiotic trials vary in strain, dose, and duration, limiting definitive recommendations on optimal formulation. The gut-skin axis is clearly a legitimate therapeutic target.
Vitamin D Supplementation Meta-Analysis (2020)
The 2020 meta-analysis (PMID 33183899) systematically reviewed RCTs examining oral vitamin D supplementation as an adjunctive intervention in psoriasis. Analysis found that supplementation significantly improved psoriasis severity scores in patients who were deficient at baseline (25-OH vitamin D below 20–30 ng/mL), while effects in vitamin D-sufficient patients were weaker and less consistent. The heterogeneity across trials — doses ranging from 1,000 to 60,000 IU, D2 vs D3 formulations, 3–12 month durations — constrains precise effect size estimates.
The mechanistic case is strong: vitamin D receptor (VDR) signaling in T cells suppresses Th17 and Th1 differentiation while promoting Treg induction, directly opposing the immune skewing that drives psoriasis. VDR signaling in keratinocytes also promotes differentiation and slows proliferation, paralleling how topical vitamin D analogues (calcipotriol) work. The smaller clinical effect of oral vitamin D compared to topical analogues reflects the lower local skin concentrations achieved through systemic supplementation — yet correcting frank deficiency reliably removes a driver of immune dysregulation.
Strength of evidence: Moderate. The evidence supports testing and correcting vitamin D deficiency in all psoriasis patients as a low-risk adjunctive intervention. Evidence for supplementing vitamin D-replete patients is not compelling. Deficiency correction is a reasonable first step before considering more targeted supplementation.
References
- A double-blind, randomised, placebo-controlled trial of fish oil in psoriasisBittiner SB, Tucker WF, Bleehen SS. The Lancet, 1988. PubMed 2893189 →
- Efficacy of fish oil and its components in the management of psoriasis: a systematic review of 18 randomized controlled trialsLuo J, Ko B, Bhatt DL, Buring JE, Cook NR. Journal of Dermatological Treatment, 2020. PubMed 31995220 →
- Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: A prospective clinical trialKurd SK, Smith N, VanVoorhees A, Beyer DR, Takeshita J, Gelfand JM. Journal of the American Academy of Dermatology, 2008. PubMed 18249471 →
- Oral Curcumin (Meriva) Is Effective as an Adjuvant Treatment and Is Able to Reduce IL-22 Serum Levels in Patients with Psoriasis VulgarisAntiga E, Bonciolini V, Volpi W, Del Bianco E, Caproni M. BioMed Research International, 2015. PubMed 26090395 →
- The role of gut microbiome in the pathogenesis of psoriasis and the therapeutic effects of probioticsChen L, Li J, Zhu W, Hui Y, Liu D, Hu Y, Zhang J, Liu H, Dai Y. Frontiers in Microbiology, 2020. PubMed 31803643 →
- Effectiveness of oral vitamin D supplementation in lessening disease severity among patients with psoriasis: A systematic review and meta-analysis of randomized controlled trialsEl-Moaty Fahim MA, Abo Alella AS, Sarhan NA, Morsy M. Journal of Dermatological Treatment, 2020. PubMed 33183899 →
Transparency
View edit historyEvery change to this page is tracked in version control. If you have conflicting research or think something is wrong, we want to hear about it.